Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hammers Discusses Immunotherapy in RCC

March 2nd 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

February 28th 2017

The FDA has granted a priority review to a biologics license application for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Biomarkers Show Efficacy of Radium-223/Docetaxel Combo in mCRPC

February 28th 2017

Michael J. Morris, MD, discusses a phase I/II trial in which the combination of radium-223 (Xofigo) and docetaxel had a greater effect than docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer.

Dr. Choueiri on the Role of Traditional Agents in Kidney Cancer

February 27th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.

Apolo Discusses Immunotherapy Advances in Bladder Cancer

February 25th 2017

Andrea Apolo, MD, discusses positive early trials exploring various regimens of nivolumab (Opdivo), ipilimumab (Yervoy), and avelumab in bladder cancer.

Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

February 24th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

Dr. Linehan on Genes With Predisposition to Kidney Cancer

February 24th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.

Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers

February 23rd 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

McDermott Discusses Promising PD-L1/VEGF Combo Findings in Frontline mRCC

February 23rd 2017

David McDermott, MD, discusses the results and the significance of the IMmotion 150 trial in metastatic renal cell carcinoma.

Dendritic Immunotherapy Falters in Phase III RCC Trial

February 23rd 2017

An Independent Data Monitoring Committee has recommended halting the phase III ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma.

Dr. McDermott on IMmotion150 Trial in RCC

February 22nd 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

First SITC Guidelines in RCC Address Continuing Role of Interleukin-2 and Emergence of Nivolumab

February 21st 2017

New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.

Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma

February 21st 2017

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies

February 21st 2017

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Combination Makes First-Line Case for Metastatic PD-L1+ RCC

February 21st 2017

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Dr. Powles on Durvalumab in Urothelial Cancer

February 20th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Checkpoint Inhibitors Continue to Offer New Hope in Urothelial Cancer

February 20th 2017

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma

February 19th 2017

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

February 18th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer

February 18th 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).